Critical Survey: Eloxx Pharmaceuticals (ELOX) and Its Competitors

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 903 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Eloxx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,309.62%	-222.80%	-17.20%

Risk and Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ competitors have a beta of -3.18, indicating that their average stock price is 418% less volatile than the S&P 500.

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.57
Eloxx Pharmaceuticals Competitors	$3.48 billion	$3.12 billion	543.71

Eloxx Pharmaceuticals’ competitors have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Eloxx Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	1	2.75
Eloxx Pharmaceuticals Competitors	7576	13627	25429	997	2.42

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, suggesting a potential upside of 154.91%. As a group, “Pharmaceuticals” companies have a potential upside of 32.43%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Eloxx Pharmaceuticals is more favorable than its competitors.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.